LabCorp Applauds National Kidney Foundation’s Guidance about Testing for Chronic Kidney Disease; LabCorp’s CKD Program

  LabCorp Applauds National Kidney Foundation’s Guidance about Testing for
  Chronic Kidney Disease; LabCorp’s CKD Program Provides Clinically
  Significant Data to Assist Diagnosis and Treatment

Business Wire

BURLINGTON, N.C. -- August 14, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) applauds
the recent recommendation of the National Kidney Foundation (NKF) that all
persons age 60 or older receive urine screening for chronic kidney disease
(CKD), defined as abnormalities of kidney structure or loss of kidney function
over time. This recommendation is an expansion of prior screening guidelines
that were based on the presence of diabetes, hypertension and other risk
factors not specifically based on age. The NKF’s announcement responds to a
study by a team of researchers from Johns Hopkins University published in the
most recent issue of the American Journal of Kidney Diseases, which found that
nearly six in ten Americans (59.1%) will develop at least moderate kidney
disease in their lifetimes, more than will develop heart disease, diabetes, or
invasive cancer. Pointing to the study, the NKF calls on physicians and
patients to practice primary prevention more aggressively, and specifically to
add urine albumin testing to annual physical examinations for high-risk groups
– those aged 60 or older and with high blood pressure or diabetes – to foster
earlier diagnosis of kidney damage. Because CKD is substantially
underdiagnosed today, it is associated with high morbidity and mortality and
is extremely costly.

The NKF estimates that 26 million Americans, most of them undiagnosed,
currently have CKD. In its earlier stages, CKD may have no symptoms and can
best be detected through routine laboratory testing. LabCorp offers testing to
detect the presence of albumin in the urine, which helps detect kidney damage
beyond that which tends to occur with normal aging, and a serum creatinine
test, from which the estimated glomerular filtration rate (eGFR), a measure of
kidney function, is calculated. As the disease progresses, complications,
including cardiovascular disease, anemia, dyslipidemia, bone disorders, and
other problems, frequently develop. Earlier diagnosis of moderate CKD can help
to delay or stop progression of CKD through lifestyle changes or medication
before those complications arise and can help prevent kidney failure requiring
dialysis or a kidney transplant.

LabCorp has developed innovative programs to assist clinicians and patients in
diagnosing and treating CKD and other chronic diseases. LabCorp provides
patient-specific results based on the leading international clinical practice
guidelines for CKD (Kidney Disease: Improving Global Outcomes, or KDIGO®).
LabCorp physicians can easily request that the CKD report be added to any of
their usual chemistry profiles (that include serum creatinine) by selecting
the additional option: LabCorp CKD Report (910343). These support tools now
accompany millions of test results from LabCorp.

Increased disease awareness, among both physicians and patients, is the first
step toward making an impact in CKD treatment. “These expanded screening
guidelines will assist in the detection of CKD in more individuals that are
currently undiagnosed and untreated, and should help more patients get
treatment before serious CKD complications arise,” said Dr.Mark Brecher,
LabCorp’s Chief Medical Officer. “The LabCorp CKD Program is another example
of LabCorp’s focus on providing physicians and their patients with clinically
significant data that will lead to earlier and better treatment and improved
health outcomes.”

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon
Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark
Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials
testing through its LabCorp Clinical Trials division. LabCorp clients include
physicians, government agencies, managed care organizations, hospitals,
clinical labs, and pharmaceutical companies. To learn more about our
organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.

Contact:

Laboratory Corporation of America^® Holdings
Investor/Media Contact:
Stephen Anderson, 336-436-5076
www.labcorp.com